Scott Fears, MD

Amae Health links wearables, AI, and biomarkers to cut rehospitalizations—now racing to prove relapse prevention gains and unlock reimbursement.

Amae Health's chief medical officer argues mental health lacks the outcome measures primary care already uses, and that wearable biomarkers could fill that gap.

Amae Health's chief medical officer discusses why Fitbit, Oura, and Apple Watch data diverge, and how AI foundation models could soon make any wearable clinically useful.

Amae Health's chief medical officer says its treated patients see 30-day rehospitalization rates of 2% to 3%, vs 20% to 25% typically, though biomarkers' exact role remains unproven.

GWAS supports psychiatry’s labels, but symptoms vary; speech biomarkers help pinpoint drivers and guide treatment across depression, OCD, schizophrenia.

Clinicians spot relapse sooner when wearable users stop charging devices—missing data becomes a signal, powering Google’s Sensor FM and Amae’s care.

Fitbit and voice biomarkers feed precision psychiatry, spotting early mood shifts and enabling low-risk interventions before crisis hits.